GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corium International Inc (NAS:CORI) » Definitions » Altman Z-Score

Corium International (Corium International) Altman Z-Score : -0.27 (As of Apr. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Corium International Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Corium International has a Altman Z-Score of -0.27, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Corium International's Altman Z-Score or its related term are showing as below:


Corium International Altman Z-Score Historical Data

The historical data trend for Corium International's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corium International Altman Z-Score Chart

Corium International Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17
Altman Z-Score
Get a 7-Day Free Trial -2.03 0.23 0.67 -2.52 -0.76

Corium International Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.73 -0.76 -2.49 -0.08 -1.46

Competitive Comparison of Corium International's Altman Z-Score

For the Biotechnology subindustry, Corium International's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corium International's Altman Z-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corium International's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Corium International's Altman Z-Score falls into.



Corium International Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Corium International's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.6888+1.4*-2.3095+3.3*-0.4156+0.6*5.3078+1.0*0.3254
=-0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Jun. 2018:
Total Assets was $112.13 Mil.
Total Current Assets was $88.92 Mil.
Total Current Liabilities was $11.68 Mil.
Retained Earnings was $-258.97 Mil.
Pre-Tax Income was -12.391 + -18.006 + -13.29 + -12.938 = $-56.63 Mil.
Interest Expense was -3.37 + -2.41 + -2.123 + -2.125 = $-10.03 Mil.
Revenue was 7.67 + 10.06 + 9.315 + 9.442 = $36.49 Mil.
Market Cap (Today) was $463.05 Mil.
Total Liabilities was $87.24 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(88.917 - 11.684)/112.131
=0.6888

X2=Retained Earnings/Total Assets
=-258.97/112.131
=-2.3095

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-56.625 - -10.028)/112.131
=-0.4156

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=463.050/87.239
=5.3078

X5=Revenue/Total Assets
=36.487/112.131
=0.3254

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Corium International has a Altman Z-Score of -0.27 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Corium International  (NAS:CORI) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Corium International Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Corium International's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Corium International (Corium International) Business Description

Traded in Other Exchanges
N/A
Address
Corium International Inc is a commercial-stage biopharmaceutical company which is focused on the development, manufacture, and commercialization of specialty pharmaceutical products. The company has multiple proprietary programs in preclinical and clinical development focusing primarily on the treatment of neurological disorders. It has few proprietary transdermal platforms such as Corplex for small molecules and MicroCor which is a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides, and proteins. The company's products include Clonidine TDS, Fentanyl TDS, and Crest Whitestrips.
Executives
Essex Woodlands Health Ventures Fund Vii Lp 10 percent owner 21 WATERWAY AVENUE, SUITE 225, THE WOODLANDS TX 77380
Robert S Breuil officer: Chief Financial Officer 2071 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Bhaskar Chaudhuri director ONE ENTERPRISE, ALISO VIEJO CA 92656
Phyllis Gardner director 618 MIRADA AVENUE, STANFORD CA 94305
Ronald W Eastman director, 10 percent owner 335 BRYANT STREET, THIRD FLOOR, PALO ALTO CA 94301
Paul Goddard director ADOLOR CORPORATION, 700 PENNSYLVANIA DR., EXTON PA 19341
David Greenwood director 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Ivan P. Gergel director C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO CA 94158
Peter D Staple director, officer: President & CEO 863 C MITTEN ROAD, BURLINGAME CA 94010
Joseph J. Sarret officer: Chief Business Officer C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Kevin Kotler 10 percent owner C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc 10 percent owner 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd 10 percent owner C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003

Corium International (Corium International) Headlines